Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients;Uso do score APRI na avaliação de doença hepática, após início de terapia antirretroviral, em pacientes portadores do HIV co-infectados com HCV versus monoinfectados por hiv

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 6, 2010, Pages 678-681

  Antonello, Vicente Sperb ^a,b,c   Tovo, Cristiane Valle ^a,c   Kliemann, Dimas Alexandre ^a   Santos, Breno Riegel ^a   Zaltron, E Vanice Ferrazza ^d  

^a HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^b Hospital Fêmina   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d Servico de Medicina Interna   (Brazil)

Author keywords

Aids; Apri; Coinfection; Hepatitis C; Hiv; Liver disease

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE;

AGE; ANALYTICAL PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LABORATORY TEST; LIVER FIBROSIS; LIVER TOXICITY; MIXED INFECTION; PATIENT MONITORING; SCORING SYSTEM; SEX DIFFERENCE; VIRUS LOAD;

HEPATITIS C VIRUS;

EID: 78650979027     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000600015     Document Type: Article

References (24)

1. Piot P, Carael M. Global Perspectives on Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. In: Mandel GL, Bennet JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th ed. Elsevier: 2009. p. 1619-1633.
2. Palella-Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Calza L, Verucchi G, Manfredi R, Chiodo F. Human Immunodeficiency Virus and Hepatitis C Virus Coinfection: Epidemiology, Natural History, Therapeutic Options and Clinical Management. Infection 2004; 32:33-46.
4. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004; 4:437-444.
5. Valle-Tovo C, Alves-de-Mattos A, Ribeiro-de-Souza A, Ferrari-de-Oliveira Rigo J, Lerias-de-Almeida PR, Galperim B, et al. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int 2007; 27:40-46.
6. Sherman KE, Roustrer SD, Chung RT, Rajicic N. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antiviral Ther 2000; 5(supl 1):64-65.
7. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, et al. Influence of HIV type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14:949-953.
8. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. HIV infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
9. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-1058.
10. Soriano V, Martin-Carbonero L, Maida I, Garcia-Samaniego J, Nunez M. New paradigms in the management of HIV and hepatitis C virus coinfection. Curr Opin Infect Dis 2005; 18:550-560.
11. Sulkowski MS, Thomas DL, Chaisson RE. Hepatotoxicity Associated with Antiretroviral Therapy in adults Infected with Human Immunodeficiency Virus and the role of Hepatitis C or B Virus Infection. JAMA 2000; 283:74-80.
12. Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 2009; 4:e4517.
13. Mariné-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, Michiels JF, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18:2163-2170.
14. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287.
15. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107-115.
16. Churg RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16:1915-1923.
17. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infec Dis 2006; 42:418-427.
18. John M, Flexman JP, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12:2289-2293.
19. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005; 40:538-544.
20. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43:78-84.
21. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
22. Ministério da Saúde. Fluxograma Mínimo para o Diagnóstico Laboratorial da Infecção pelo HIV em Indivíduos com Idade acima de 18 Meses. Ministério da Saúde. Secretaria de Vigilância em Saúde; 2009. Disponível em: http://www.aids.gov.br.
23. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immune deficiency virus infection. Clin Infect Dis 2001; 32: 492-497.
24. Rockville (MD): National Institute of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. AIDS Clinical Trials Group Division of AIDS for grading the severity of adult and pediatric adverse advents; 2004.